Tình trạng pháp lý: API giai đoạn thương mại, có CEP châu Âu và hồ sơ DMF đa khu vực
Tên IUPAC: 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one;hydrochloride
Số EC: 664-451-0
Khối lượng phân tử: 525.1
Công thức hoá học: C₂₃H₃₃ClN₆O₄S
Số CAS: 224785-91-5
Ứng dụng: Thuốc uống ức chế PDE5 điều trị rối loạn cương dương
Dạng bào chế: Dạng đa hình trihydrat (API)
Status: Commercial
Therapeutic cat.: Erectile
Polymorphic form: Trihydrate form

Thông tin khác

Mô tả thêm:

Established in 1935 and based in the Greater Poland Voivodeship, Polpharma is a manufacturer and service provider of active pharmaceutical ingredients spanning prophylactic biological products, central nervous system drugs, cardiovascular system drugs and related APIs, offering CDMO contract manufacturing to markets across North America, Latin America, Western and Eastern Europe, Australasia, Asia, the Middle East and Africa. Drawing on 75 years of experience in the API business, Polpharma API covers the full value chain from R&D through production and supply chain management to project management, operating from a European base with R&D and two manufacturing plants, and specializes in high-potency APIs (OEB 5&6), high-potency ADC payloads, advanced linker technologies, customizable ADC development solutions, cryogenic reactions and oligonucleotides. The company is recognized for international certification, an experienced R&D team, strong reputation, high-quality service and a genuinely global market presence.